Literature DB >> 30948872

Prognostic Value of Metastatic Lymph Node Ratio in Pancreatic Cancer.

Can A Karaca1,2, Ahmet Coker3.   

Abstract

Lymph node involvement in pancreatic adenocancer is one of the strongest predictors of prognosis. However, the extent of lymph node dissection is still a matter of debate and number of dissected nodes varies widely among patients. In order to homogenize this diverse group of patients and more accurately predict their prognosis, we aimed to analyze the effect of metastatic lymph node ratio as an independent prognostic factor. We retrospectively analyzed medical recordings of 326 patients with pancreatic cancer who were treated in a tertiary medical oncology center over a 10-year period. Both in univariate and multivariate analyses, metastatic lymph node ratio proved to be a strong predictor of prognosis which was unaffected from heterogeneity of our patient population and can be used to facilitate predict prognosis of patients who underwent lymph node dissection to various extents and with future studies it can emerge as a successful tool for creating prognostic subgroups of the disease.

Entities:  

Keywords:  Metastatic lymph node ratio; Pancreatic cancer; Prognostic value

Year:  2018        PMID: 30948872      PMCID: PMC6414569          DOI: 10.1007/s13193-018-0824-9

Source DB:  PubMed          Journal:  Indian J Surg Oncol        ISSN: 0975-7651


  29 in total

Review 1.  Extended lymph node dissection in gastric carcinoma: where do we stand after the Dutch and British randomized trials?

Authors:  Yasuhiro Kodera; Roderich E Schwarz; Akimasa Nakao
Journal:  J Am Coll Surg       Date:  2002-12       Impact factor: 6.113

2.  1423 pancreaticoduodenectomies for pancreatic cancer: A single-institution experience.

Authors:  Jordan M Winter; John L Cameron; Kurtis A Campbell; Meghan A Arnold; David C Chang; Joann Coleman; Mary B Hodgin; Patricia K Sauter; Ralph H Hruban; Taylor S Riall; Richard D Schulick; Michael A Choti; Keith D Lillemoe; Charles J Yeo
Journal:  J Gastrointest Surg       Date:  2006-11       Impact factor: 3.452

3.  Feasibility of a randomized trial of extended lymphadenectomy for pancreatic cancer.

Authors:  Timothy M Pawlik; Eddie K Abdalla; Carlton C Barnett; Syed A Ahmad; Karen R Cleary; Jean-Nicolas Vauthey; Jeffrey E Lee; Douglas B Evans; Peter W T Pisters
Journal:  Arch Surg       Date:  2005-06

4.  Extent of lymph node retrieval and pancreatic cancer survival: information from a large US population database.

Authors:  Roderich E Schwarz; David D Smith
Journal:  Ann Surg Oncol       Date:  2006-09-06       Impact factor: 5.344

5.  Improved survival and local control after total mesorectal excision or D3 lymphadenectomy in the treatment of primary rectal cancer: an international analysis of 1411 patients.

Authors:  K Havenga; W E Enker; J Norstein; Y Moriya; R J Heald; H C van Houwelingen; C J van de Velde
Journal:  Eur J Surg Oncol       Date:  1999-08       Impact factor: 4.424

6.  A prospective randomized trial comparing standard pancreatoduodenectomy with pancreatoduodenectomy with extended lymphadenectomy in resectable pancreatic head adenocarcinoma.

Authors:  Michael B Farnell; Randall K Pearson; Michael G Sarr; Eugene P DiMagno; Lawrence J Burgart; Tamela R Dahl; Nathan Foster; Daniel J Sargent
Journal:  Surgery       Date:  2005-10       Impact factor: 3.982

7.  Long-term results of partial pancreaticoduodenectomy for ductal adenocarcinoma of the pancreatic head: 25-year experience.

Authors:  Axel Richter; Marco Niedergethmann; Jörg W Sturm; Dietmar Lorenz; Stefan Post; Michael Trede
Journal:  World J Surg       Date:  2003-02-27       Impact factor: 3.352

8.  The metastatic/examined lymph node ratio is an important prognostic factor after pancreaticoduodenectomy for pancreatic adenocarcinoma.

Authors:  Adam C Berger; James C Watson; Eric A Ross; John P Hoffman
Journal:  Am Surg       Date:  2004-03       Impact factor: 0.688

9.  Prognostic relevance of lymph node ratio following pancreaticoduodenectomy for pancreatic cancer.

Authors:  Timothy M Pawlik; Ana L Gleisner; John L Cameron; Jordan M Winter; Lia Assumpcao; Keith D Lillemoe; Christopher Wolfgang; Ralph H Hruban; Richard D Schulick; Charles J Yeo; Michael A Choti
Journal:  Surgery       Date:  2007-03-23       Impact factor: 3.982

10.  Pancreaticoduodenectomy with or without distal gastrectomy and extended retroperitoneal lymphadenectomy for periampullary adenocarcinoma, part 2: randomized controlled trial evaluating survival, morbidity, and mortality.

Authors:  Charles J Yeo; John L Cameron; Keith D Lillemoe; Taylor A Sohn; Kurtis A Campbell; Patricia K Sauter; JoAnn Coleman; Ross A Abrams; Ralph H Hruban
Journal:  Ann Surg       Date:  2002-09       Impact factor: 12.969

View more
  2 in total

1.  The role of lymph node status in cancer-specific survival and decision-making of postoperative radiotherapy in poorly differentiated thyroid cancer: a population-based study.

Authors:  Maojie Zhang; Siyi Lei; Yuanyi Chen; Yuzhou Wu; Hui Ye
Journal:  Am J Transl Res       Date:  2021-01-15       Impact factor: 4.060

2.  Multivisceral resection for adenocarcinoma of the pancreatic body and tail-a retrospective single-center analysis.

Authors:  Oliver Beetz; Akin Sarisin; Alexander Kaltenborn; Jürgen Klempnauer; Michael Winkler; Gerrit Grannas
Journal:  World J Surg Oncol       Date:  2020-08-20       Impact factor: 2.754

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.